Futility stopping in non-inferiority trials
نویسندگان
چکیده
منابع مشابه
Futility stopping in clinical trials
Early stopping due to futility, also referred to as a go/nogo decision, during interim analysis has become an important feature of clinical trial designs. Current methods for futility stopping in literature are mostly based on conditional power or predictive power in conjunction with the theory of stochastic curtailment or group sequential design. They have certain drawbacks that have been note...
متن کاملEquivalence and non inferiority trials
Many effective drugs, biologics and devices exist. Because of this, it is often considered unethical to undertake placebo controlled clinical trials to evaluate new treatments. Rather, randomized active control noninferiority trials have become the norm. These trials, however, are accompanied by serious issues including selecting an active comparator, identifying previously run active comparato...
متن کاملBio-creep in non-inferiority clinical trials.
After a non-inferiority clinical trial, a new therapy may be accepted as effective, even if its treatment effect is slightly smaller than the current standard. It is therefore possible that, after a series of trials where the new therapy is slightly worse than the preceding drugs, an ineffective or harmful therapy might be incorrectly declared efficacious; this is known as 'bio-creep'. Several ...
متن کاملCurrent issues in non-inferiority trials.
Non-inferiority (NI) trials enable a direct comparison of the relative benefit-to-risk profiles of an experimental intervention and a standard-of-care regimen. When the standard has clinical efficacy of substantial magnitude that is precisely estimated ideally using data from multiple adequate and well-controlled trials, with such estimates being relevant to the setting of the NI trial, then th...
متن کاملEquivalence and Non-inferiority Trials of CAM
For several reasons, the value of placebo-controlled trials has often been disputed (not only) in complementary/alternative medicine (CAM) (1). Many clinicians feel that giving placebos to suffering patients is unethical. In fact, the Declaration of Helsinki advocates placebo-controlled trials only for conditions for which no therapy of proven efficacy exists (2). Other frequently cited reasons...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Contemporary Clinical Trials Communications
سال: 2019
ISSN: 2451-8654
DOI: 10.1016/j.conctc.2018.100314